Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Moleculin Biotech	Ocuphire Pharma	AzurRx BioPharma	PhaseBio Pharmaceuticals	Assertio
Symbol	NASDAQ:MBRX	NASDAQ:OCUP	NASDAQ:AZRX	NASDAQ:PHAS	NASDAQ:ASRT
Price Information
Current Price	$3.42	$4.69	$0.81	$2.96	$0.53
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.2	1.9	1.4	1.5	1.6
Analysis Score	3.5	3.5	3.4	3.5	3.5
Community Score	2.7	4.4	3.0	2.3	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	0.0	0.8	0.8
Earnings & Valuation Score	0.0	0.6	0.6	0.6	1.3
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$15.00	$21.75	$3.50	$12.33	$3.50
% Upside from Price Target	338.60% upside	363.75% upside	332.10% upside	316.67% upside	560.38% upside
Trade Information
Market Cap	$97.28 million	$51.26 million	$62.81 million	$87.15 million	$90.33 million
Beta	2.11	0.76	1.81	1.85	1.68
Average Volume	2,762,954	338,129	8,707,146	582,597	15,410,241
Sales & Book Value
Annual Revenue	N/A	N/A	N/A	$2.36 million	$229.50 million
Price / Sales	N/A	N/A	N/A	36.93	0.40
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.34 per share	$9.91 per share	$0.17 per share	$2.09 per share	$0.72 per share
Price / Book	N/A	N/A	N/A	1.42	0.74
Profitability
Net Income	$-13,200,000.00	$-8,640,000.00	$-15,180,000.00	$-39,250,000.00	$-217,200,000.00
EPS	($0.32)	N/A	N/A	($1.43)	($3.07)
Trailing P/E Ratio	N/A	0.00	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	-145.15%
Return on Equity (ROE)	-113.25%	-79.33%	-316.41%	-220.57%	-259.36%
Return on Assets (ROA)	-63.20%	-58.43%	-162.80%	-110.30%	-55.13%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	1.87%	1.02%
Current Ratio	4.44%	2.88%	4.40%	4.39%	0.80%
Quick Ratio	4.44%	2.88%	4.40%	4.39%	0.69%
Ownership Information
Institutional Ownership Percentage	4.82%	63.71%	5.14%	58.58%	39.95%
Insider Ownership Percentage	8.30%	1.10%	7.30%	17.00%	2.69%
Miscellaneous
Employees	11	5	10	50	27
Shares Outstanding	28.44 million	10.93 million	74.44 million	29.44 million	173.45 million
Next Earnings Date	5/10/2021 (Estimated)	5/6/2021 (Estimated)	5/21/2021 (Estimated)	5/11/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Assertio (ASRT) Stock Jumps And Falls Quickly: A Bearish Signal? – Own Snap - Own Snap ownsnap.com - April 16 at 6:22 AM
	Is Assertio Holdings Inc (ASRT) a Leader in the Drug Manufacturers - Specialty & Generic Industry? - InvestorsObserver investorsobserver.com - April 15 at 5:20 PM
	30 Stocks Moving In Thursday's Mid-Day Session - Benzinga benzinga.com - April 15 at 12:19 PM
	22 Stocks Moving in Thursday's Pre-Market Session - Benzinga benzinga.com - April 15 at 7:17 AM
	Why Assertio Holdings Inc (ASR) stock is rallying on Thursday’s pre-market? - Market Globalist marketglobalist.com - April 15 at 7:17 AM
	Assetio (ASRT) Stock Has Lost Almost All Its This Year Gain – Own Snap - Own Snap ownsnap.com - April 14 at 1:00 PM
	Assertio Holdings, Inc. (NASDAQ:ASRT) Forecast to gain 181.82% to hit Consensus price target marketingsentinel.com - April 14 at 1:39 AM
	Assertio (NASDAQ:ASRT) Upgraded to "Buy" at Gabelli americanbankingnews.com - April 13 at 7:10 PM
	Airline Stocks - Assertio Holdings Inc. (ASRT), JetBlue Airways Corporation (JBLU) have attractive valuations – BOV News - Fintech Zoom fintechzoom.com - April 13 at 3:32 PM
	Wall Street Roundup: Bullish & Bearish Calls Of The Day - Yahoo Finance finance.yahoo.com - April 12 at 11:07 PM
	Benzinga's Top Ratings Upgrades, Downgrades For April 9, 2021 - Benzinga benzinga.com - April 11 at 9:18 AM
	Trading Penny Stocks? 5 You Can Buy Under $1 On Robinhood Right Now - Penny Stocks pennystocks.com - April 9 at 9:46 AM
	Global Gabapentin Market 2021 Top Manufactures – Pfizer, Intas, Assertio Therapeutics, Mylan, Arbor Pharma, TEVA, Sun Pharmaceutical – FLA News - FLA News flanewsonline.com - April 8 at 8:16 AM
	Analysts Conflicted on These Healthcare Names: Assertio Therapeutics (NASDAQ: ASRT), Frequency Therapeutics (NASDAQ: FREQ) and Cardiol Therapeutics (Other OTC: CRTPF) - Analyst Ratings analystratings.com - April 6 at 10:43 AM
	Assertio (NASDAQ:ASRT) Earns "Hold" Rating from Gabelli americanbankingnews.com - April 6 at 8:16 AM
	Assertio (ASRT) Surges 60% So Far This Year: What Next? – Own Snap - Own Snap ownsnap.com - April 5 at 7:24 AM
	Assertio Holdings, Inc. (NASDAQ:ASRT)’s stock falls -1.99%, but it may be worth investing in stocksregister.com - March 29 at 9:57 AM
	Hot Penny Stocks To Watch Before April 2021 \| FinancialContent Business Page - Financial Content markets.financialcontent.com - March 26 at 5:50 PM
	Assertio Holdings, Inc. (NASDAQ:ASRT) Down Almost -25.27% in 1 Month, But Long Term Looking Good marketingsentinel.com - March 26 at 12:49 PM
	InvestorNewsBreaks – Assertio Holdings Inc. (NASDAQ: ASRT) Closes $14M, $34.3M Registered Direct Offerings - StreetInsider.com streetinsider.com - March 16 at 6:35 PM
	Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options - Yahoo Finance finance.yahoo.com - March 15 at 5:31 PM
	Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options - Nasdaq nasdaq.com - March 15 at 12:30 PM
	3 Penny Stocks To Buy Under $1 On Webull, Fidelity & Others Right Now - StreetInsider.com streetinsider.com - March 14 at 9:27 PM
	Assertio reports decline in sales - Chicago Daily Herald dailyherald.com - March 13 at 1:18 AM
	Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 12 at 3:17 PM

Date	Company	Brokerage	Action
6/25/2020	Moleculin Biotech	Oppenheimer	Reiterated Rating
6/9/2020	Moleculin Biotech	Maxim Group	Initiated Coverage
11/18/2019	Moleculin Biotech	Roth Capital	Reiterated Rating
4/5/2021	Ocuphire Pharma	Alliance Global Partners	Initiated Coverage
3/29/2021	Ocuphire Pharma	Jonestrading	Initiated Coverage
3/22/2021	Ocuphire Pharma	Cantor Fitzgerald	Boost Price Target
2/10/2021	Ocuphire Pharma	Canaccord Genuity	Initiated Coverage
4/14/2021	AzurRx BioPharma	HC Wainwright	Reiterated Rating
1/6/2021	AzurRx BioPharma	Dawson James	Downgrade
6/11/2019	AzurRx BioPharma	National Securities	Initiated Coverage
3/22/2021	PhaseBio Pharmaceuticals	Needham & Company LLC	Boost Price Target
3/18/2021	PhaseBio Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
8/25/2020	PhaseBio Pharmaceuticals	Citigroup	Lower Price Target
9/24/2019	PhaseBio Pharmaceuticals	Cowen	Reiterated Rating
9/11/2019	PhaseBio Pharmaceuticals	William Blair	Reiterated Rating
4/13/2021	Assertio	Gabelli	Upgrade
9/18/2020	Assertio	G.Research	Reiterated Rating
6/3/2020	Assertio	Brookline Capital Management	Initiated Coverage
5/16/2019	Assertio	Mizuho	Lower Price Target
8/29/2018	Assertio	Janney Montgomery Scott	Downgrade

(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources